Avalo Therapeutics secures AVTX-009 and $185 million in funding, poised for breakthroughs in inflammatory disease treatments
The acquisition of AVTX-009 represents a key milestone for Avalo as it aims to address the significant unmet needs in severe autoimmune diseases like HS. Dr. Garry A. Neil, CEO and Chairman of Avalo, expressed confidence in the potential of AVTX-009 to emerge as a best-in-class treatment option. The company’s focus on inflammatory conditions aligns well with its strategic vision, backed by recent data validating the inhibition of IL-1β in diseases like HS.
Patrick J. Crutcher, former CEO of AlmataBio, highlighted the promise of AVTX-009 and expressed optimism about its advancement into Phase 2 trials under Avalo’s stewardship. The acquisition underscores Avalo’s commitment to identifying and accelerating the development of clinically meaningful therapies.
With the private placement financing, Avalo expects to extend its cash runway into 2027, providing ample resources to support operations and the development of AVTX-009. The financing deal, led by prominent investors, reflects confidence in Avalo’s strategic direction and the potential of its pipeline candidates.
Avalo’s leadership team remains unchanged, ensuring continuity in driving the company’s growth trajectory. With the completion of the acquisition and financing transactions, Avalo is well-positioned to advance AVTX-009 through clinical trials and further strengthen its position in the field of inflammatory disease therapeutics.
Read original press release:here
You might like this article:Viking Therapeutics’ Breakthrough Oral Tablet Spurs Excitement in Weight Loss Trials
